ProQR Therapeutics BV

Healthcare · Biotechnology

1.60$ -3.7% vs. previous close Closing price · As of: Oct 8, 2026

Statements

Cash Flow

ProQR Therapeutics BV (PRQR) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -12 million EUR. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size % Per share

Last 12 Full history

Download as CSV

All figures in millions of EUR.

Tick rows to compare them in a chart (up to 4)

Cash Flow PRQR
Line item	Q3 16	Q4 16	Q1 17	Q2 17	Q3 17	Q4 17	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26	LTM
Operating Cash Flow	-11	-7.3	-8.8	-9.8	-7.6	-8.7	-9.7	-5.4	-4.3	-11	-12	-11	-8.8	-12	-15	-10	-9.8	-12	-12	-10.0	-8.1	3.8	-20	-15	-15	-18	45	-10	-7.5	-5.3	-15	-6.3	-5.7	-9.3	-16	-11	-12	-13	-11	-12	-49
Depreciation & Amortization	0.3	0.3	0.3	0.3	0.3	0.3	0.2	0.2	0.2	0.3	0.5	0.5	0.5	0.5	0.5	0.5	0.7	0.7	0.6	0.6	0.5	0.6	0.6	0.6	0.6	0.7	0.5	0.6	0.6	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	2.8
Stock-Based Compensation	0.6	0.5	0.9	1.3	0.9	0.9	0.9	0.6	0.7	1.0	2.3	1.1	1.2	4.5	2.9	1.8	1.7	1.5	1.2	1.5	1.7	1.8	1.2	0.7	1.3	-0.4	1.1	0.8	0.4	0.8	0.7	0.6	0.6	0.6	0.8	0.9	1.1	1.2	1.4	1.4	5.1
Adjustments to Net Income	–	2.2	1.5	2.5	1.8	7.5	2.0	0.4	0.9	5.8	1.7	0.8	0.1	6.0	2.7	-6.0	3.0	2.6	1.6	3.3	1.8	2.1	-2.5	-1.4	5.0	-1.5	0.7	0.7	–	–	–	–	–	–	–	–	–	–	–	–	–
Change in Working Capital	-1.8	2.0	-0.1	-1.3	0.8	0.7	-0.9	1.4	0.7	0.2	-0.5	-0.5	2.7	0.0	-2.2	-0.9	-0.3	-2.0	-1.0	1.8	4.8	19	-4.0	0.9	3.6	-5.7	52	-3.6	-2.0	2.3	-9.2	-4.6	1.1	-0.5	-6.7	-1.2	-3.1	-6.3	0.1	-5.8	-15
Capital Expenditures	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.2	0.1	0.0	0.2	0.2	0.3	0.3	0.1	0.0	0.1	0.2	0.2	0.2	0.2	0.2	0.0	0.1	0.3	0.3	0.6	0.7	0.3	0.3	0.1	0.2	0.1	0.2	0.5	0.2	0.3	1.1
Investing Cash Flow	-0.4	0.0	0.0	0.0	0.0	0.0	0.0	-0.2	-0.1	0.0	-0.2	-0.1	0.0	-0.2	-0.2	-0.3	-0.3	-0.1	0.0	-0.1	-0.2	-0.2	-0.2	-0.2	-0.2	0.0	-0.1	-0.3	-0.3	5.0	-18	-0.3	17	-2.8	-0.2	-0.1	-0.2	-0.5	-0.2	-0.3	-1.1
Dividends Paid	–	–	–	–	–	–	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Stock Buybacks / Issuance	–	0.0	2.2	1.1	5.5	27	0.0	0.0	0.0	128	0.0	0.2	0.2	49	0.5	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Net Borrowings	–	0.4	0.1	0.1	0.3	1.0	0.4	0.1	0.1	1.5	0.4	-0.3	-0.3	1.6	0.1	0.2	13	0.2	-0.2	0.6	-0.1	27	-0.6	-0.4	-44	-0.4	-0.6	-0.6	–	–	–	–	-0.5	-0.3	-0.6	-0.3	-0.4	-0.6	-0.3	-0.6	-2.0
Financing Cash Flow	0.2	0.2	2.2	1.2	5.8	18	0.3	0.1	85	3.2	0.5	-0.2	-0.3	50	0.6	0.5	13	0.2	3.0	83	24	27	-0.5	-0.4	-44	14	-0.3	-0.6	-0.3	-1.1	-0.4	-0.3	-0.5	71	-0.5	-0.3	-0.4	-0.6	-0.3	49	48
Change in Cash	-11	-5.7	-7.1	-9.8	-2.6	8.4	-10	-5.0	81	-8.1	-12	-12	-7.7	37	-14	-11	1.7	-13	-8.0	72	17	31	-20	-11	-56	-5.7	44	-10	-8.0	-1.6	-33	-6.7	10	60	-17	-13	-13	-15	-11	35	-3.3
Free Cash Flow	-11	-7.4	-8.8	-9.9	-7.6	-8.7	-9.7	-5.6	-4.4	-11	-13	-11	-8.8	-12	-15	-11	-10	-12	-12	-10	-8.2	3.6	-21	-15	-16	-18	45	-11	-7.8	-5.9	-16	-6.5	-5.9	-9.5	-16	-12	-12	-14	-11	-13	-50

LTM = last twelve months (sum of the four most recent quarters).

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Cash Flow

Cookie settings